# A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.

> **NCT00000856** · PHASE1 · WITHDRAWN · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)**

## Conditions studied

- Encephalopathy
- HIV Infections
- Radiculitis

## Interventions

- **DRUG:** Foscarnet sodium
- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT00000856
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2021-10-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00000856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00000856, "A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00000856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*